Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population : High Vaccine-Type–Specific Effectiveness and Evidence of Cross-Protection

• Material Type: 博士論文
• Title: Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population : High Vaccine-Type–Specific Effectiveness and Evidence of Cross-Protection
• Author/Editor: Kudo, Risa
• Publication, Distribution, etc.: 新潟大学
• Publication Date: 2019-03-25
• Publication Date (W3CDTF): 2019-03-25
• Alternative Title: Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population : High Vaccine-Type–Specific Effectiveness and Evidence of Cross-Protection; 日本人における2価HPVワクチンの効果 : 主標的型に対する高いHPV感染予防効果と交叉防御能の証明
• Degree grantor/type: 新潟大学
• Date Granted: 2019-03-25
• Date Granted (W3CDTF): 2019-03-25
• Dissertation Number: 甲第4527号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 甲第4527号
• Text Language Code: eng
• Note (General): Background. Proactive recommendations for human papillomavirus (HPV) vaccines in Japan have been suspended for 5 years because of safety concerns. While no scientific evidence exists to substantiate these concerns, one reason given for not reinstating recommendations is the lack of reliable vaccine effectiveness (VE) data in a Japanese population. This study reports the VE of the bivalent HPV vaccine in Japanese women aged 20–22 years. Methods. During cervical screening between 2014 and 2016, women had Papanicolaou smears and HPV tests performed and provided data about their sexual history. Estimates of VE for vaccine-targeted HPV type 16 (HPV16) and 18 and cross-protection against other types were calculated. Results. Overall, 2197 women were tested, and 1814 were included in the analysis. Of these, 1355 (74.6%) were vaccinated, and 1295 (95.5%) completed the 3-dose schedule. In women sexually naive at vaccination, the pooled VEs against HPV16 and 18 and for HPV31, 45, and 52 were 95.5% (P < .01) and 71.9% (P < .01), respectively. When adjusted for number of sex partners and birth year, pooled VEs were 93.9% (P = .01) and 67.7% (P = .01) for HPV16 and 18 and HPV31, 45, and 52, respectively. Conclusions. The bivalent HPV vaccine is highly effective against HPV16 and 18. Furthermore, significant cross-protection against HPV31, 45, and 52 was demonstrated and sustained up to 6 years after vaccination. These findings should reassure politicians about the VE of bivalent HPV vaccine in a Japanese population.; 学位の種類: 博士（医学）. 報告番号: 甲第4527号. 学位記番号: 新大院博（医）甲第849号. 学位授与年月日: 平成31年3月25日; 新大院博（医）甲第849号; 元資料の権利情報 : 【○!C】The Author(s) .
• Persistent ID (NDL): info:ndljp/pid/11498336; https://dl.ndl.go.jp/pid/11498336
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2020-06-07T00:39:19+09:00
• Date Created (W3CDTF): 2019-09-10
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://hdl.handle.net/10191/51315
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp